Celesio AG (CLSGn.DE)
17.70EUR
11:35am EDT
€-0.04 (-0.23%)
€17.06
€17.89
€17.99
€17.52
716,634
520,823
€18.00
€12.81
CLSGn.DE
About
Overall
| Beta: | 0.82 |
| Market Cap (Mil.): | €3,017.57 |
| Shares Outstanding (Mil.): | 170.10 |
| Dividend: | 0.30 |
| Yield (%): | 1.69 |
Financials
| CLSGn.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 30.51 | 18.16 | 37.16 |
| EPS (TTM): | 0.58 | -- | -- |
| ROI: | 2.33 | 9.92 | 64.31 |
| ROE: | 4.18 | 11.17 | 70.34 |
Exclusive: U.S. drug firms vie to take stake in Celesio - sources
FRANKFURT - Two U.S. drugs distribution groups McKesson Corp and Cardinal Health Inc are both in talks to possibly take a stake in German drugs company Celesio , two industry sources familiar with the situation said.
Haniel denies in talks with CVS to sell Celesio stake
DUESSELDORF, Germany - Diversified holding company Franz Haniel & Cie said on Wednesday it was not in talks with U.S. drugstore chain CVS to sell majority control over German drug distributor Celesio .
UPDATE 1-Haniel denies in talks with CVS to sell Celesio stake
* CVS prepared to pay Celesio 2 bln eur for stake -magazine
Haniel says not in talks with CVS to sell Celesio stake
DUESSELDORF, Germany, June 19 - Diversified holding company Franz Haniel & Cie on Wednesday said it was not in talks with U.S. group CVS to sell its 50.01 percent stake in German drug distributor Celesio, denying an earlier press report.
Celesio Q1 core profit drops on competition in home market
FRANKFURT, May 14 - Celesio, Europe's largest drugs distributor, posted a steeper-than-expected decline in core earnings as harsh competition prompted a slide in prices charged to German pharmacies.
Haniel says has no plans to cut Celesio stake
FRANKFURT, May 6 - Diversified holding company Franz Haniel & Cie. said it has no plans to further reduce its stake in German drugs distributor Celesio, rebuffing a media report.
BRIEF-Celesio says wants to end price war in German drugs distribution
FRANKFURT, March 26 - Celesio AG : * CEO says have seen unprecedented price war in pharmacy business in Germany,
Celesio 2012 core earnings up 9.5 pct on cost cuts
FRANKFURT, March 26 - German drugs distributor Celesio said 2012 core earnings gained 9.5 percent as it reduced costs to counter cutbacks in European healthcare budgets.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
